Skip to main content

Publications

Found 16 results
[ Author(Desc)] Title Year
Filters: Author is Laura A Magee  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
M
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. The CHIPS Randomized Controlled Trial (Control of Hypertension in Pregnancy Study): Is Severe Hypertension Just an Elevated Blood Pressure?. Hypertension. 2016;68(5):1153-1159.  (476.19 KB)
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. Can adverse maternal and perinatal outcomes be predicted when blood pressure becomes elevated? Secondary analyses from the CHIPS (Control of Hypertension In Pregnancy Study) randomized controlled trial. Acta Obstet Gynecol Scand. 2016;95(7):763-76.  (803.67 KB)
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. Control of Hypertension In Pregnancy Study randomised controlled trial-are the results dependent on the choice of labetalol or methyldopa?. BJOG. 2016;123(7):1135-41.  (144.71 KB)
Magee LA, von Dadelszen P, Singer J, Lee T, Rey E, Ross S, et al.. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG. 2016;123(7):1143-51.  (153.93 KB)
Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P. The hypertensive disorders of pregnancy (29.3). Best Pract Res Clin Obstet Gynaecol. 2015;29(5):643-57.  (227.04 KB)
Magee LA, Singer J, von Dadelszen P. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015;372(24):2367-8.  (515.75 KB)
Magee LA, von Dadelszen P, Asztalos E, Ross S, Rey E. 34 weeks of gestation-lost in translation. J Obstet Gynaecol Can. 2014;36(6):480-481.  (706.24 KB)
Magee LA, von Dadelszen P, Allen V, Ansermino JM, Audibert F, Barrett J, et al.. The Canadian Perinatal Network: a national network focused on threatened preterm birth at 22 to 28 weeks' gestation. J Obstet Gynaecol Can. 2011;33(2):111-120.  (322.85 KB)
Magee LA, Sawchuck D, Synnes A, von Dadelszen P, Basso M, Crane J, et al.. Magnesium Sulphate for Fetal Neuroprotection. Journal of Obstetrics and Gynaecology Canada. 2011;33(5):516 - 529.  (298.54 KB)
Magee LA, Namouz-Haddad S, Cao V, Koren G, von Dadelszen P. Labetalol for hypertension in pregnancy. Expert Opin Drug Saf. 2015;14(3):453-61.  (463.16 KB)
Magee LA, Helewa M, Rey E. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2008;30(3 Suppl):S1-S2.  (1.73 MB)
Magee LA, von Dadelszen P. Prevention and treatment of postpartum hypertension. Cochrane Database Syst Rev. 2013;(4):CD004351.  (447.63 KB)
Magee LA, Lowe S, M Douglas J, Kathirgamanathan A. Therapeutics and anaesthesia. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):477-90.  (187.9 KB)
Magee LA, Côté A-M, Joseph G, Firoz T, Sia W. Obstetric medical care in Canada. Obstet Med. 2016;9(3):117-9.  (81.97 KB)
Magee LA, Synnes A, von Dadelszen P, Hutfield A, Chanoine J-P, Côté A-M, et al.. CHIPS-Child: Testing the developmental programming hypothesis in the offspring of the CHIPS trial. Pregnancy Hypertens. 2018;14:15-22.  (1011.52 KB)
Magee LA, Sharma S, Nathan H, Adetoro OO, Bellad MB, Goudar S, et al.. The incidence of pregnancy hypertension in India, Pakistan, Mozambique, and Nigeria: A prospective population-level analysis. PLoS Med. 2019;16(4):e1002783.  (864.32 KB)